Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.40 |
| ▸ | LTB4R2 | Q9NPC1 | 4/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6774063 | 0.90 | LTB4R2 (0.50) | TSHRLMNALPAR1LTB4R2TAS1R3 | |
| SCHEMBL6782897 | 0.86 | TSHR (0.44) | TSHRLMNAHIF1ALPAR1LTB4R2 | |
| SCHEMBL6778194 | 0.80 | TSHR (0.44) | TSHRLMNAHIF1ALPAR1LTB4R2 | |
| SCHEMBL6774704 | 0.79 | TSHR (0.47) | TSHRLMNAHIF1ALPAR1LTB4R2 | |
| SCHEMBL6784314 | 0.79 | HIF1A (0.46) | TSHRLMNAHIF1ALPAR1LTB4R2 | |
| SCHEMBL6780992 | 0.77 | TSHR (0.45) | TSHRLMNAHIF1ALPAR1LTB4R2 | |
| SCHEMBL6774057 | 0.76 | LMNA (0.46) | TSHRLMNALPAR1LTB4R2ALDH1A1 | |
| SCHEMBL6778886 | 0.74 | MCHR1 (0.43) | TSHRLMNAHIF1ALPAR1MCHR1 | |
| SCHEMBL6783768 | 0.73 | LPAR1 (0.51) | TSHRLPAR1LTB4R2MCHR1 | |
| SCHEMBL6781046 | 0.73 | MEN1 (0.49) | TSHRLMNALTB4R2TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020156281-A1 | Amide inhibitors of microsomal triglyceride transfer protein | BOOTH RICHARD JOHN (US) | 2002-10-24 | — | — | US | claimed |
| US-6780883-B2 | ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS; ANTILIPEMIC AGENTS; RESTENOSIS; DIETETICS | WARNER-LAMBERT COMPANY | 2004-08-24 | — | — | US | disclosed |
| US-20020156281-A1 | Amide inhibitors of microsomal triglyceride transfer protein | BOOTH RICHARD JOHN (US) | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156281-A1 | Amide inhibitors of microsomal triglyceride transfer protein | CETP, MTTP, LCAT | TSHR 1297/4885LMNA 4203/4885HIF1A 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.